Neuropsychiatric complications of interferons: Classification, neurochemical bases, and management

Parviz Malek-Ahmadi, Robin C. Hilsabeck

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background. Recombinant interferons are widely used for a number of serious illnesses. However, their use is sometimes associated with severe and disabling neuropsychiatric side effects. Methods. A MEDLINE search identified pertinent laboratory investigations, case reports, clinical studies and letters published between 1983 and 2004 in the English language journals. The studies in which interferons were used in combination with other cytokines were excluded. Results. The interferon-associated neuropsychiatric side effects are divided into mood-related symptoms (depression/mania), cognitive impairment (including delirium), psychosis and isolated psychiatric symptoms. Putative neurotransmitters (serotonin and dopamine), hormones (cortisol) and cyokines (interleukin-2 and 6) have been implicated in the pathophysiology of these side effects. Management of neuropsychiatric side effects of interferons ranges from supportive measures, dose reduction, cessation of therapy and the use of appropriate psychotropic agents. Conclusions. Interferon-treated patients should be monitored for mental status changes. There are no controlled studies on pharmacological management of interferon-induced neuropsychiatric side effects. The use of interferons in patients with stable psychiatric disorders is not contraindicated. However, such patients should be closely monitored during the course of treatment with interferons.

Original languageEnglish (US)
Pages (from-to)113-123
Number of pages11
JournalAnnals of Clinical Psychiatry
Volume19
Issue number2
DOIs
StatePublished - Apr 2007
Externally publishedYes

Fingerprint

Interferons
Psychiatry
Delirium
Bipolar Disorder
MEDLINE
Psychotic Disorders
Interleukin-2
Neurotransmitter Agents
Hydrocortisone
Interleukin-6
Dopamine
Serotonin
Language
Hormones
Pharmacology
Depression
Cytokines
Therapeutics

Keywords

  • Cognitive deficits
  • Interferons
  • Management
  • Mood-related symptoms
  • Neurotransmitters/Cytokines
  • Psychosis

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Neuropsychiatric complications of interferons : Classification, neurochemical bases, and management. / Malek-Ahmadi, Parviz; Hilsabeck, Robin C.

In: Annals of Clinical Psychiatry, Vol. 19, No. 2, 04.2007, p. 113-123.

Research output: Contribution to journalArticle

Malek-Ahmadi, Parviz ; Hilsabeck, Robin C. / Neuropsychiatric complications of interferons : Classification, neurochemical bases, and management. In: Annals of Clinical Psychiatry. 2007 ; Vol. 19, No. 2. pp. 113-123.
@article{c9f87edc9781403eaf35db30a7008acb,
title = "Neuropsychiatric complications of interferons: Classification, neurochemical bases, and management",
abstract = "Background. Recombinant interferons are widely used for a number of serious illnesses. However, their use is sometimes associated with severe and disabling neuropsychiatric side effects. Methods. A MEDLINE search identified pertinent laboratory investigations, case reports, clinical studies and letters published between 1983 and 2004 in the English language journals. The studies in which interferons were used in combination with other cytokines were excluded. Results. The interferon-associated neuropsychiatric side effects are divided into mood-related symptoms (depression/mania), cognitive impairment (including delirium), psychosis and isolated psychiatric symptoms. Putative neurotransmitters (serotonin and dopamine), hormones (cortisol) and cyokines (interleukin-2 and 6) have been implicated in the pathophysiology of these side effects. Management of neuropsychiatric side effects of interferons ranges from supportive measures, dose reduction, cessation of therapy and the use of appropriate psychotropic agents. Conclusions. Interferon-treated patients should be monitored for mental status changes. There are no controlled studies on pharmacological management of interferon-induced neuropsychiatric side effects. The use of interferons in patients with stable psychiatric disorders is not contraindicated. However, such patients should be closely monitored during the course of treatment with interferons.",
keywords = "Cognitive deficits, Interferons, Management, Mood-related symptoms, Neurotransmitters/Cytokines, Psychosis",
author = "Parviz Malek-Ahmadi and Hilsabeck, {Robin C.}",
year = "2007",
month = "4",
doi = "10.1080/10401230701333038",
language = "English (US)",
volume = "19",
pages = "113--123",
journal = "Annals of Clinical Psychiatry",
issn = "1040-1237",
publisher = "Dowden Health Media,Inc",
number = "2",

}

TY - JOUR

T1 - Neuropsychiatric complications of interferons

T2 - Classification, neurochemical bases, and management

AU - Malek-Ahmadi, Parviz

AU - Hilsabeck, Robin C.

PY - 2007/4

Y1 - 2007/4

N2 - Background. Recombinant interferons are widely used for a number of serious illnesses. However, their use is sometimes associated with severe and disabling neuropsychiatric side effects. Methods. A MEDLINE search identified pertinent laboratory investigations, case reports, clinical studies and letters published between 1983 and 2004 in the English language journals. The studies in which interferons were used in combination with other cytokines were excluded. Results. The interferon-associated neuropsychiatric side effects are divided into mood-related symptoms (depression/mania), cognitive impairment (including delirium), psychosis and isolated psychiatric symptoms. Putative neurotransmitters (serotonin and dopamine), hormones (cortisol) and cyokines (interleukin-2 and 6) have been implicated in the pathophysiology of these side effects. Management of neuropsychiatric side effects of interferons ranges from supportive measures, dose reduction, cessation of therapy and the use of appropriate psychotropic agents. Conclusions. Interferon-treated patients should be monitored for mental status changes. There are no controlled studies on pharmacological management of interferon-induced neuropsychiatric side effects. The use of interferons in patients with stable psychiatric disorders is not contraindicated. However, such patients should be closely monitored during the course of treatment with interferons.

AB - Background. Recombinant interferons are widely used for a number of serious illnesses. However, their use is sometimes associated with severe and disabling neuropsychiatric side effects. Methods. A MEDLINE search identified pertinent laboratory investigations, case reports, clinical studies and letters published between 1983 and 2004 in the English language journals. The studies in which interferons were used in combination with other cytokines were excluded. Results. The interferon-associated neuropsychiatric side effects are divided into mood-related symptoms (depression/mania), cognitive impairment (including delirium), psychosis and isolated psychiatric symptoms. Putative neurotransmitters (serotonin and dopamine), hormones (cortisol) and cyokines (interleukin-2 and 6) have been implicated in the pathophysiology of these side effects. Management of neuropsychiatric side effects of interferons ranges from supportive measures, dose reduction, cessation of therapy and the use of appropriate psychotropic agents. Conclusions. Interferon-treated patients should be monitored for mental status changes. There are no controlled studies on pharmacological management of interferon-induced neuropsychiatric side effects. The use of interferons in patients with stable psychiatric disorders is not contraindicated. However, such patients should be closely monitored during the course of treatment with interferons.

KW - Cognitive deficits

KW - Interferons

KW - Management

KW - Mood-related symptoms

KW - Neurotransmitters/Cytokines

KW - Psychosis

UR - http://www.scopus.com/inward/record.url?scp=34447119531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447119531&partnerID=8YFLogxK

U2 - 10.1080/10401230701333038

DO - 10.1080/10401230701333038

M3 - Article

C2 - 17612851

AN - SCOPUS:34447119531

VL - 19

SP - 113

EP - 123

JO - Annals of Clinical Psychiatry

JF - Annals of Clinical Psychiatry

SN - 1040-1237

IS - 2

ER -